Study of the effect of GABAA receptore and glial inhibition on behavioral responses in CCI model of neuropathic pain in rat

Background: The mechanisms underlying neuropathic pain are complex and remain controversial. From the proposed mechanisms we can refer to loss of GABAergic inhibition and glial activation in the spinal dorsal horn. As for the discrepancies in the neuropathic pain mechanisms, in the present study, we...

Full description

Bibliographic Details
Main Authors: Mehi Sadeghi, Homa Manaheji, Abbad Haghparast, Jalal Zaringhalam, Samad Nazemi, Zahra Bahari
Format: Article
Language:English
Published: Bushehr University of Medical Sciences 2015-01-01
Series:Iranian South Medical Journal
Subjects:
CCI
Online Access:http://ismj.bpums.ac.ir/browse.php?a_code=A-10-3-542&slc_lang=en&sid=1
id doaj-ad41e4b2f3fa4048bbf8892db6e531dc
record_format Article
spelling doaj-ad41e4b2f3fa4048bbf8892db6e531dc2020-11-24T21:04:22ZengBushehr University of Medical SciencesIranian South Medical Journal 1735-43741735-69542015-01-0117611201134Study of the effect of GABAA receptore and glial inhibition on behavioral responses in CCI model of neuropathic pain in ratMehi Sadeghi0Homa Manaheji1Abbad Haghparast2Jalal Zaringhalam3Samad Nazemi4Zahra Bahari5 Department of physiology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, IRAN<br> Department of Neurophysiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IRAN Neuroscice Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IRAN<br> Department of Neurophysiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IRAN Neuroscice Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IRAN Neuroscice Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IRAN<br> Department of Neurophysiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IRAN Department of physiology, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, IRAN Department of Neurophysiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IRAN Background: The mechanisms underlying neuropathic pain are complex and remain controversial. From the proposed mechanisms we can refer to loss of GABAergic inhibition and glial activation in the spinal dorsal horn. As for the discrepancies in the neuropathic pain mechanisms, in the present study, we examined whether the GABA-A receptor agonist muscimol and glial inhibitor pentoxifylline would modify behavioral tests in rats with Chronic Constriction Injury (CCI). Material and Methods: In this study male wistar rats (200-250 g) were used and for neuropathy induction, the CCI model (Bennett method, 1988) was used. In the sham group, after exposing the sciatic nerve, surgery region was closed. Pentoxifylline was administered one day before neuropathy to 14 days after CCI (30 mg/kg daily) and behavioral tests (plantar test and von frey) were performed one day before surgery and then on days 1, 4, 7 and 14 after surgery and 30 minutes after pentoxifylline adminstration .In groups that received muscimol with doses 0.5, 1 and 2 mg/kg on day 14 after CCI, behavioral tests were experienced before and 30 minutes after drug administration. Results: Behavioral assessment indicated that CCI induce symptoms of neuropathic pain but both muscimol and pentoxifylline could reduce pain behavioral responses. It seems that this reduction of muscimol (1 and 2 mg/kg) was more effective in thermal hyperalgesia than pentoxifylline, and for pentoxifylline (30 mg/kg) was more effective in mechanical allodynia than muscimol. Conclusion: present data showed that muscimol via activation of GABA-A receptors and pentoxifylline via glial inhibition reduced behavioral symptoms of neuropathic pain after spinal cord injury.http://ismj.bpums.ac.ir/browse.php?a_code=A-10-3-542&slc_lang=en&sid=1neuropathic pain hyperalgesia allodynia CCI muscimol pentoxifylline
collection DOAJ
language English
format Article
sources DOAJ
author Mehi Sadeghi
Homa Manaheji
Abbad Haghparast
Jalal Zaringhalam
Samad Nazemi
Zahra Bahari
spellingShingle Mehi Sadeghi
Homa Manaheji
Abbad Haghparast
Jalal Zaringhalam
Samad Nazemi
Zahra Bahari
Study of the effect of GABAA receptore and glial inhibition on behavioral responses in CCI model of neuropathic pain in rat
Iranian South Medical Journal
neuropathic pain
hyperalgesia
allodynia
CCI
muscimol
pentoxifylline
author_facet Mehi Sadeghi
Homa Manaheji
Abbad Haghparast
Jalal Zaringhalam
Samad Nazemi
Zahra Bahari
author_sort Mehi Sadeghi
title Study of the effect of GABAA receptore and glial inhibition on behavioral responses in CCI model of neuropathic pain in rat
title_short Study of the effect of GABAA receptore and glial inhibition on behavioral responses in CCI model of neuropathic pain in rat
title_full Study of the effect of GABAA receptore and glial inhibition on behavioral responses in CCI model of neuropathic pain in rat
title_fullStr Study of the effect of GABAA receptore and glial inhibition on behavioral responses in CCI model of neuropathic pain in rat
title_full_unstemmed Study of the effect of GABAA receptore and glial inhibition on behavioral responses in CCI model of neuropathic pain in rat
title_sort study of the effect of gabaa receptore and glial inhibition on behavioral responses in cci model of neuropathic pain in rat
publisher Bushehr University of Medical Sciences
series Iranian South Medical Journal
issn 1735-4374
1735-6954
publishDate 2015-01-01
description Background: The mechanisms underlying neuropathic pain are complex and remain controversial. From the proposed mechanisms we can refer to loss of GABAergic inhibition and glial activation in the spinal dorsal horn. As for the discrepancies in the neuropathic pain mechanisms, in the present study, we examined whether the GABA-A receptor agonist muscimol and glial inhibitor pentoxifylline would modify behavioral tests in rats with Chronic Constriction Injury (CCI). Material and Methods: In this study male wistar rats (200-250 g) were used and for neuropathy induction, the CCI model (Bennett method, 1988) was used. In the sham group, after exposing the sciatic nerve, surgery region was closed. Pentoxifylline was administered one day before neuropathy to 14 days after CCI (30 mg/kg daily) and behavioral tests (plantar test and von frey) were performed one day before surgery and then on days 1, 4, 7 and 14 after surgery and 30 minutes after pentoxifylline adminstration .In groups that received muscimol with doses 0.5, 1 and 2 mg/kg on day 14 after CCI, behavioral tests were experienced before and 30 minutes after drug administration. Results: Behavioral assessment indicated that CCI induce symptoms of neuropathic pain but both muscimol and pentoxifylline could reduce pain behavioral responses. It seems that this reduction of muscimol (1 and 2 mg/kg) was more effective in thermal hyperalgesia than pentoxifylline, and for pentoxifylline (30 mg/kg) was more effective in mechanical allodynia than muscimol. Conclusion: present data showed that muscimol via activation of GABA-A receptors and pentoxifylline via glial inhibition reduced behavioral symptoms of neuropathic pain after spinal cord injury.
topic neuropathic pain
hyperalgesia
allodynia
CCI
muscimol
pentoxifylline
url http://ismj.bpums.ac.ir/browse.php?a_code=A-10-3-542&slc_lang=en&sid=1
work_keys_str_mv AT mehisadeghi studyoftheeffectofgabaareceptoreandglialinhibitiononbehavioralresponsesinccimodelofneuropathicpaininrat
AT homamanaheji studyoftheeffectofgabaareceptoreandglialinhibitiononbehavioralresponsesinccimodelofneuropathicpaininrat
AT abbadhaghparast studyoftheeffectofgabaareceptoreandglialinhibitiononbehavioralresponsesinccimodelofneuropathicpaininrat
AT jalalzaringhalam studyoftheeffectofgabaareceptoreandglialinhibitiononbehavioralresponsesinccimodelofneuropathicpaininrat
AT samadnazemi studyoftheeffectofgabaareceptoreandglialinhibitiononbehavioralresponsesinccimodelofneuropathicpaininrat
AT zahrabahari studyoftheeffectofgabaareceptoreandglialinhibitiononbehavioralresponsesinccimodelofneuropathicpaininrat
_version_ 1716771376051781632